Long-term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: an Integrated Analysis with Over 9600 Patient-Years of exposure. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 10, n. 2, p. s727, 2026. DOI: 10.25251/evafb145. Disponível em: https://skin.dermsquared.com/skin/article/view/4035. Acesso em: 17 apr. 2026.